Skip to main content
Clinical Trials/NCT06453850
NCT06453850
Recruiting
Not Applicable

Safety and Performance Evaluation of a New Catheter Range for Lead Implantation At Interventricular Septum

MicroPort CRM3 sites in 2 countries216 target enrollmentFebruary 14, 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bradycardia
Sponsor
MicroPort CRM
Enrollment
216
Locations
3
Primary Endpoint
Absence of Unanticipated Serious Adverse Device Effect (USADE) related to FLEXIGO delivery catheter
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of the clinical investigation is to evaluate the safety of the FLEXIGO delivery catheter for transvenous pacing lead implantation.

Registry
clinicaltrials.gov
Start Date
February 14, 2025
End Date
December 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
MicroPort CRM
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Absence of Unanticipated Serious Adverse Device Effect (USADE) related to FLEXIGO delivery catheter

Time Frame: 72 hours after implantation

Any event caused by use of the FLEXIGO delivery catheter or any accessory packaged with the catheter, will be considered as an ADE related to the FLEXIGO delivery catheter. The primary endpoint evaluation will be based on Sponsor assessment of safety events, based on investigational site reporting.

Secondary Outcomes

  • Left Bundle Branch Area Pacing (LBBAP) implantation success rate per indication (cardiac pacing and CRT) and per ventricular pacing lead model(During implantation)
  • Implantation success rates(During implantation)
  • Implantation usability(During implantation)
  • Serious Adverse Device Effect (SADE) rate related to FLEXIGO delivery catheter or the slitter(72 hours after implantation)
  • Implantation time(During implantation)

Study Sites (3)

Loading locations...

Similar Trials